Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ-II: Long-term Outcomes of Viekira Pak in HCV GT1
NCT02167945Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2014
- Primary completion
- May 2021
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of paritaprevir, ombitasvir, dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Jun 2014; status: completed.
02
Drugs
paritaprevirombitasvirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02167945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02167945.